PepGen Inc. (PEPG) stock intrinsic value fair value estimate & owner earnings analysis

PepGen is a clinical-stage biotechnology company with no revenue. Its Enhanced Delivery Oligonucleotide (EDO) platform uses cell-penetrating peptides to improve the uptake and activity of attached oligonucleotide drugs for severe neuromuscular and neurologic diseases. Its only clinical candidate is PGN-EDODM1 for myotonic dystrophy type 1 (DM1). The drug is designed to bind the expanded CUG repeats in the DMPK messenger RNA and free the splicing factor MBNL1, correcting the downstream mis-splicing that drives the disease. In the single-dose Phase 1 FREEDOM study, the company reported dose-dependent splicing correction but no meaningful functional improvement over placebo after one dose. The multiple-dose Phase 2 FREEDOM2 study is open in Canada, the United Kingdom, South Korea, Australia and New Zealand. As of the March 2026 annual report, the FDA had placed a partial clinical hold on FREEDOM2 in the U.S. over questions about earlier preclinical pharmacology and toxicology studies. News reports in August 2026 said an independent safety board recommended moving FREEDOM2 into its highest-dose cohort. PGN-EDODM1 has FDA orphan drug and Fast Track designations. The company's second program, PGN-EDO51 for Duchenne muscular dystrophy, was stopped in May 2025 after the 10 mg/kg cohort of the CONNECT1 trial did not reach target dystrophin levels. How we measured it: we take operating cash flow, strip out working-capital swings, and subtract stock compensation and capital spending. Because there are no sales, we treat all capital spending as upkeep, and we treat rent on the company's lease as an ongoing cost. On that basis owner earnings were about -$81.8 million in 2023, -$92.1 million in 2024 and -$89.4 million in 2025. The business has never produced positive cash, so there is no earnings level to capitalize. The real question is how much of the cash on hand shareholders ever get back. The loss narrowed only about 3% in 2025, but spending has fallen since the Duchenne program was dropped. In the first half of 2026 the net loss was $35.6 million, against $53.3 million a year earlier. R&D fell to $25.5 million from $43.8 million, operating cash outflow was $34.2 million, and each quarter lost about $17.8 million. Our cases use that lower pace, about $68 million a year in cash or roughly 16% below 2025's $81.6 million outflow. They rest on those two quarters and the dated program cut, not on any new revenue. Balance sheet: at June 30, 2026 the company held $117.2 million in cash and marketable securities and had no borrowings. At the end of 2025 its only liabilities were payables, accrued costs and its facility lease. Remaining lease payments totalled $21.9 million, running $3.2 to $3.6 million a year through 2030 and $5.0 million after that. The company says the $148.5 million it held at the end of 2025 funds its current plan into the second half of 2027. It raised $107.6 million net in September 2025 by selling about 35.9 million shares at $3.20. There were 69.3 million shares outstanding in August 2026, and funds affiliated with RA Capital owned 29.2% at the end of 2025. What we credit: there is no product revenue, license income or signed partnership. So no case credits future sales of PGN-EDODM1 or any value for the platform, because clinical success is something the business has not yet achieved or secured. This is the largest judgement in the analysis. It is why each case turns on how much cash is spent before the story ends. All cases discount at 6%. With no debt, nothing is owed to lenders in any case. The only claims ahead of shareholders are the lease and the cost of closing down, which we set at about $12 million to settle payables and accrued trial costs (these stood at $9.5 million at the end of 2025), close trials and pay severance. Bear case (-$0.34 per share): the company spends all its cash on the current plan by the second half of 2027, as its own runway implies, and nothing licensable results. With no cash left, it would still owe about $12.4 million (present value) in lease payments from 2028 onward plus the roughly $12 million close-out cost. The company would owe about $23 million more than it is worth. Base case (-$0.15 per share): development continues at the first-half-2026 pace through 2027, in line with the program moving to higher doses, leaving about $15 million at the end of 2027. After close-out costs and lease payments from 2028, the business is worth about $10 million less than nothing. In effect, shareholders' cash is committed to a program whose payoff cannot yet be shown from the filings. Bull case ($0.74 per share): the company stops after the 10 mg/kg FREEDOM2 readout it guided to the second half of 2026, as it did with the Duchenne program in May 2025. That leaves about $83 million at the end of 2026. After close-out costs and $15.5 million (present value) of lease payments from 2027 onward, about $51 million would be left for shareholders in today's money. Margin-of-safety price: at today's level of spending, the value of the shares rests on the chance that PGN-EDODM1 succeeds, and the filings give no basis to value that. The margin-of-safety price applies only if the company stops spending on the program and commits to wind down or return its cash while it still holds roughly $80 million. The shares would then be worth about $0.74, and the margin-of-safety price is $0.45. The margin is wide because the lease settlement, close-out costs and timing are uncertain. What would make this wrong: a partnership or license that brings in upfront cash, or strong multiple-dose data that leads to one, would create value we have not counted. Spending faster than the first-half-2026 pace would lower every case.